Sunday, May 18, 2025 5/18/2025

SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants

Award Number: R21CA229069
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants - This application is being submitted as an Administrative Supplement in response to the Notice of Special Interest (NOSI) identified as NOT-CA-20-042. Study of highly infectious diseases, especially those caused by viruses, poses unique biosafety challenges to the scientific research community. Rather than lose the insights this research can provide, common workarounds exist to reduce the risk of studying infectious virus by examining the proteins encoded by the virus in the absence of a fully infectious particle. This approach has been employed for many other viruses and has been proven effective in obtaining valuable data. However, viruses like SARS-CoV-2 mutate leading to many different strains and sequence variations, and it can be difficult to predict which mutations alter virus transmission, infection symptoms, or vaccine / treatment efficacy. Given that cancer patients constitute an at-risk population for Covid-19, this is even more complicated in the context of how cancer cells affect virus infection or how the virus affects cancer progression. Methods to examine virus protein mutations in a high throughput, systematic, and comprehensive (i.e. every mutation) manner are completely lacking. To help address this challenge, we propose to harness our innovative high throughput mutagenesis strategy to comprehensively generate plasmids of every possible point mutation of the SARS-CoV-2 S “spike” protein as the key viral recognition protein of the human entry receptor, towards accelerating functional studies and vaccine development. The resulting plasmid set is especially useful for functional assays to identify critical S protein variants, which is a vital area of current Covid-19 research. The S protein mutant plasmid set will be validated by expression of the variant plasmids in human cells and determination of which variants bind to different commercially available SARS-CoV-2 S protein antibodies. These results will be confirmed by immunofluorescence staining. While we envision these variants being employed by the cancer research community in their model systems, they can be used equally effectively by the SARS-CoV-2 research community in general. The proposed method significantly improves on random mutagenesis by error-prone PCR by avoiding its substantial mutational bias and ensuring exactly one mutation per plasmid for streamlined analysis. This strategy will be confirmed by next generation sequencing (NGS), comparing against error-prone PCR. Following successful validation assays for the S protein variant pool, we will generate mutant plasmid sets for three additional key proteins encoded by the SARS-CoV-2 genome. This Administrative Supplement is within the scope of our parent IMAT award, which is a technology development R21 mechanism, to generate all mutants of three key oncoproteins and link the expressed protein variants back to specific feature locations on a microarray. Upon successful completion of this Administrative Supplement, we intend to prepare a SBIR Phase I to sort each individual SARS-CoV-2 mutant plasmid into distinct wells of multiwell plates for additional availability to the Covid-19 research community.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$6,305 )
2025	2022	PROTEOVISTA LLC	510 CHARMANY DR STE 57	MADISON	WI	53719	DANE	USA	Cancer Biology Research	000	3	10/9/2024	NON-COMPETING CONTINUATION	$0
2025	2020	PROTEOVISTA LLC	510 CHARMANY DR STE 57	MADISON	WI	53719	DANE	USA	Cancer Detection and Diagnosis Research	001	2	12/4/2024	SUPPLEMENT FOR EXPANSION	-$6,305
														Subtotal = -$6,305

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	PROTEOVISTA LLC	510 CHARMANY DR	MADISON	WI	53719	DANE	USA	Cancer Biology Research	000	3	8/25/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $110,028 )
2022	2022	PROTEOVISTA LLC	510 CHARMANY DRIVE, SUITE 57	MADISON	WI	53719	DANE	USA	Cancer Biology Research	000	3	5/6/2022	NON-COMPETING CONTINUATION	$110,028
														Subtotal = $110,028

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	PROTEOVISTA LLC	510 CHARMANY DRIVE, SUITE 57	MADISON	WI	53719	DANE	USA	Cancer Biology Research	000	2	8/6/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $297,460 )
2020	2020	PROTEOVISTA LLC	510 CHARMANY DRIVE, SUITE 57	MADISON	WI	53719	DANE	USA	Cancer Detection and Diagnosis Research	001	2	9/14/2020	SUPPLEMENT FOR EXPANSION	$129,050
2020	2020	PROTEOVISTA LLC	510 CHARMANY DRIVE, SUITE 57	MADISON	WI	53719	DANE	USA	Cancer Biology Research	000	2	4/28/2020	NON-COMPETING CONTINUATION	$168,410
														Subtotal = $297,460

Issue Date FY: 2019 ( Subtotal = $168,410 )
2019	2019	PROTEOVISTA LLC	510 CHARMANY DRIVE, SUITE 57	MADISON	WI	53719	DANE	USA	Cancer Biology Research	000	1	4/30/2019	NEW	$168,410
														Subtotal = $168,410

Grand Total All Awards = $569,593

Top

All Categories

About

Search

Reports

Data Submission

Award Information

SNAP-X: Development of a Mutagenesis Strategy and High Density Protein Array to Comprehensively Display Protein Variants

Award Number: R21CA229069

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer